MTARC1 and metabolic dysfunction-associated steatotic liver disease: Further mechanistic studies are warranted to characterize the molecular mechanism of mARC1 action in the liver to refine our understanding of this target in the pathogenesis of MASLD and to explore whether the loss of mARC1 may have additive or synergistic effects with other liver-directed therapies.